Athyrium invests in a wide range of financial instruments including royalties, structured credit, and equities as well as select special situations.
Athyrium has over $600 million under management.
Horizon Pharma Announces Pricing of $150 Million of 5.00% Convertible Senior Notes
InnoPharma Inc. Completes $20 Million Term Loan Facility
Verenium Enters Agreement to be Acquired by BASF
bioMerieux to Acquire BioFire Diagnostics for $450 Million Plus Net Financial Debt
Tria Beauty, Inc. Announces the Closing of $45.5 Million in New Equity Financing and a New Structured Debt Facility.
BioFire Diagnostics, Inc. Expands Financing Commitment from Athyrium Opportunities Fund to $45 Million
Athyrium Commits $31.25 Million to Progenity, Inc. in the Form of a Secured Term Loan and Preferred Stock
Athyrium is a specialized asset management company with over $600 million under management. Athyrium invests in a wide range of financial instruments including royalties, structured credit, and equities as well as select special situations....
Limited Partnership Interests
Sign up for updates and news from Athyrium Capital Management. Your email will not be distributed or used for any third party purposes.